Get started
Author

Özgecan Dülgar

Observed names: O. Dulgar, Ozgecan Dulgar, Ozgecan Dulgar Kaya, Ö. Dülgar, ÖZGECAN DÜLGAR, Özgecan Dulgar, Özgecan DÜLGAR, Özgecan Dülgar Kaya, Özgecan Dülger Kaya
Observed institutions: Moffitt Cancer Center, İstanbul Eğitim ve Araştırma Hastanesi, Ümraniye Eğitim ve Araştırma Hastanesi, Istanbul University-Cerrahpaşa, Bakırköy Dr.Sadi Konuk Eğitim ve Araştırma Hastanesi, Sağlık Bilimleri Üniversitesi, Medeniyet Üniversitesi Göztepe Eğitim ve Araştırma Hastanesi, Istanbul Medeniyet University, Istanbul University
ORCID: 0000-0002-0678-4024
Observed ORCID: 0000-0002-0678-4024
OpenAlex ID: A5030410773
Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer
2023 · Seda Kahraman, Enes Erul, et al. · Future Oncology · 27
Mechanisms of Resistance to BRAF-Targeted Melanoma Therapies
2020 · Ozgecan Dulgar, Tugce Kutuk, et al. · American Journal of Clinical Dermatology · 25
Efficacy and toxicity of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapy
2023 · Prachi Bhave, Angela Hong, et al. · Journal for ImmunoTherapy of Cancer · 22
PDF
FOLFIRINOX versus gemcitabine plus nab-paclitaxel as the first-line chemotherapy in metastatic pancreatic cancer
2022 · Seval Ay, Muhammed Mustafa Atcı, et al. · Journal of Chemotherapy · 20
Prognostic Factors and Tumor Infiltrating Lymphocytes in Triple Negative Breast Cancer
2020 · Ozgecan Dulgar, Sennur Ilvan, et al. · European Journal of Breast Health · 12
PDF
Prognostic value of aldehyde dehydrogenase 1 (ALDH1) in invasive breast carcinomas
2018 · Hale Demir, Ozgecan Dulgar, et al. · Bosnian Journal of Basic Medical Sciences · 12
PDF
Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia on efficacy: a Turkish Oncology Group (TOG) study
2024 · Hasan Cagri Yildirim, Caner Kapar, et al. · Journal of Chemotherapy · 10
The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study
2024 · Hasan Çağrı Yıldırım, Yasin Kutlu, et al. · International Journal of Clinical Oncology · 10
Initial Ca 125 Value as a Predictive Marker for High-grade Serous Ovarian Cancer
2021 · Seval Ay, Deniz Tataroglu Ozyukseler, et al. · Journal of College of Physicians And Surgeons Pakistan · 9
PDF
Prognostic factors of perioperative FLOT regimen in operable gastric and gastroesophageal junction tumors: real-life data (Turkish Oncology Group)
2022 · CİHAN EROL, ABDULLAH SAKİN, et al. · TURKISH JOURNAL OF MEDICAL SCIENCES · 8
PDF
Real-World Treatment Efficacy of Ribociclib or Palbociclib Plus Fulvestrant in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study
2025 · Seda Kahraman, Enes Erul, et al. · Clinical Breast Cancer · 7
Successful Treatment with Carboplatin and Paclitaxel in Melanoma Progression After Immune-Related Adverse Events
2023 · Özgecan Dülgar, Aditi Saha, et al. · Immunotherapy · 6
PDF
Long-lasting response with polycythemia to third-line axitinib treatment in metastatic renal cell carcinoma: Very rare case presentation
2018 · Ozgecan Dulgar, Ibrahim Cil, et al. · Journal of Oncology Pharmacy Practice · 6
Is adipose tissue metabolic activity a predictor of pathological responses to neoadjuvant treatment in breast cancer
2022 · Ozgecan Dulgar, Ebru Orsal Ibisoglu, et al. · Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) · 4
Pleural tuberculosis in a patient with untreated type 1 Gaucher disease
2015 · Ozgecan Dulgar, Ahmet Emre Eskazan, et al. · Journal of Infection and Chemotherapy · 4
Is the benefit of using adjuvant capecitabine in patients with residual triple-negative breast cancer related to pathological response to neoadjuvant chemotherapy?
2022 · Özgecan Dülgar, Başak Bala Öven, et al. · Expert Review of Anticancer Therapy · 3
Prognostic impact of histopathological features and serum inflammatory markers in patients with gastric cancer undergoing neoadjuvant therapy
2025 · Nilufer Bulut, Gokmen U Erdem, et al. · World Journal of Gastrointestinal Surgery · 2
PDF
The Relationship of Tumor-infiltrating Lymphocyte Ratio with Histopathological Parameters and Effect on Survival in Colorectal Cancers
2024 · İsra Serda Oğuz, Sinan Koca, et al. · Turkish Journal of Colorectal Disease · 2
PDF
Sleep Quality Analysis in Metastatic Breast Cancer Patients Receiving Cyclin-Dependent Kinase 4-6 Inhibitor
2022 · Özgecan DÜLGAR, Sevgi FERİK, et al. · Journal of Oncological Sciences · 2
PDF
Efficacy of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapy.
2021 · Prachi Bhave, Angela M. Hong, et al. · Journal of Clinical Oncology · 2
Role of tumor location on high-grade serous ovarian cancer prognosis
2021 · Seval Ay, Deniz Tataroğlu Özyükseler, et al. · Ginekologia Polska · 2
PDF
Is the duration of castration resistance predictive for sequential treatment responses in the metastatic castration-resistant prostate cancer setting?
2020 · Özgecan Dülgar, Deniz Tataroğlu Özyükseler, et al. · Journal of Oncology Pharmacy Practice · 2
First-Line Treatment After Perioperative FLOT in Recurrent Gastric and Gastroesophageal Junction Cancer: A Turkish Oncology Group (TOG) Multicenter Real-World Analysis
2026 · Mustafa Seyyar, Pervin Can Şancı, et al. · Medicina · 1
HER2-low expression in patients with hormone receptor positive and HER2 negative advanced breast cancer treated with ribociclib or palbociclib in combination with endocrine therapy
2025 · Seda Kahraman, Mutlu Hızal, et al. · Turkish Journal of Clinics and Laboratory · 1
PDF
Extraordinary Benefit of Regorafenib in Metastatic Cholangiocarcinoma: A Case Report
2025 · Ayberk Bayramgil, Tugce Kubra Gunes, et al. · Current Cancer Drug Targets · 1
Works count: 48
Citation count: 206
H-index: 9
I10-index: 8
Year
Topic
Type